A New Location for Islet Transplants: Why the Spleen Might Change Type 1 Diabetes Treatment

For people with Type 1 diabetes, islet transplantation offers a potential path to reduce or stop insulin injections. The procedure involves taking insulin-producing islet cells from a donor pancreas and placing them into the recipient's body, where they can resume their natural job of controlling blood sugar.

Currently, transplanted islets are placed into the liver through the portal vein, where they settle in small blood vessels. However, this location presents serious problems. The liver's environment—including immune attack, low oxygen, and stiff tissue—destroys roughly 70% of the transplanted cells before they can even begin working. This massive cell loss means patients often need islets from multiple donors to achieve meaningful results, and even then, success rates remain limited.

Because liver transplantation has such significant drawbacks, scientists have explored other sites in the body for islet placement, including the eye, abdominal lining (omentum), and muscle tissue. Each alternative location has introduced new problems—invasive surgery, poor cell survival, or abnormal patterns of insulin release.

Researchers at Wenzhou Medical University took a different approach. They asked whether the spleen might be a better home for transplanted islets.

The key to making spleen transplantation successful was preparing the tissue first using specially designed nanoparticles. These nanoparticles remodeled the spleen's environment before the islet cells were transplanted, creating conditions more favorable for cell survival and function.

In studies, this method restored normal blood sugar control in diabetic rodents and also in cynomolgus macaques (primates). Remarkably, the transplanted islets functioned without requiring full immunosuppression—the heavy medication regimen typically needed to prevent the immune system from attacking transplanted cells.

If this approach proves successful in human studies, it could significantly improve islet transplantation as a treatment option. A spleen-based transplant that requires less immunosuppression would mean fewer medications and their associated side effects for patients, and potentially better long-term outcomes.

However, this research was conducted in animals. Before this technique can be offered to patients, it must advance through human clinical trials to confirm that it is safe and effective. The path from animal research to approved human treatment typically takes several years.

Origin: medicalxpress.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.